XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long-Term Investments (Tables)
 3 Months Ended
Mar. 31, 2024
Long-Term Investments [Abstract]  
Schedule of Ownership Percentages of Each Investee The ownership percentages of each investee are listed as follows:
   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2024   2023   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.67%   0.67%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method
BioFirst Corporation   18.68%   18.68%  Equity Method
Rgene Corporation   26.65%   26.65%  Equity Method

 
Schedule of Extent the Investee Relies The extent the investee relies on the company for its business are summarized as follows:
Name of related party   The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs
Schedule of Long-Term Investment Long-term investment mainly consists of the following:
   March 31,
2024		   December 31,
2023		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $6,904   $7,213 
Genepharm Biotech Corporation   21,078    22,021 
BioHopeKing Corporation   782,995    818,018 
Sub total   810,977    847,252 
Equity Method Investments, net          
BioFirst Corporation   1,663,537    1,680,488 
Rgene Corporation   
-
    
-
 
Total  $2,474,514   $2,527,740 
Schedule of Balance Sheet Balance Sheet
   March 31,
2024		   December 31,
2023		 
   (Unaudited)     
Current Assets  $1,439,444   $1,451,877 
Non-current Assets   651,560    686,206 
Current Liabilities   2,663,111    2,286,058 
Non-current Liabilities   101,908    347,193 
Stockholders’ Equity (Deficit)   (674,015)   (495,168)

 

   March 31,
2024		   December 31,
2023		 
   (Unaudited)     
Current Assets  $49,496   $50,538 
Non-current Assets   238,193    250,716 
Current Liabilities   2,535,581    2,591,960 
Non-current Liabilities   1,194    811 
Shareholders’ Deficit   (2,249,086)   (2,291,517)
Schedule of Statement of Operation Statement of Operations
   Three months Ended
March 31,		 
   2024   2023 
   (Unaudited) 
Net sales  $363   $
-
 
Gross profit   220    
-
 
Net loss   (203,077)   (406,233)
Share of losses from investments accounted for using the equity method   
-
    
-
 
   Three months Ended
March 31,		 
   2024   2023 
   (Unaudited) 
Net sales  $
-
   $
-
 
Gross Profit   
-
    
-
 
Net loss   (56,567)   (81,842)
Share of loss from investments accounted for using the equity method   
-
    
-
 
Schedule of Loss on Investment in Equity Securities The components of losses on equity investments for each period were as follows:
   Three months Ended
March 31,		 
   2024   2023 
   (Unaudited) 
Share of equity method investee losses  $
      -
   $
       -